Post Reply
3181-3200 of 10899
Disappointing counter....faster go up so I could sell off...
Go by chart for direction. It is still safer. Dont be greedy. 
bishan22 ( Date: 10-Mar-2011 15:05) Posted:
|
this counter jialat...nv break through 1.20. No dividend some more...
http://www.ocbcresearch.com/Article.aspx?type=research&id=20110314090739_88224
Do not think the delay will be long. Though I do believe for this week and early part of next, MHLW will be too busy with the quake. But further delay to Nobori's approval Japan's disadvantage - 1) With tightening of budget to cope with aftermath of quake, why continue to pay for foreign stents when they can get their own Nobori. 2) Trial of Nobori already planned in Kyoto university for May 2011 3) Stenting surgery are essential surgery and so impact from econony will be minimal.
Still hopeful it will be approved end March or latest early april. In 2009 one of the stent was approved late March, hope this will again be the case Nobori...
Looks like there will be more delay bec of the quake?? Same old story for BIG.....??
While the mkt is eagerly awaiting the approval of the Nobori DES in Japan, the question arises - What next ?. Will this be the end of the uptrend for Biosensors, once the news is out ? How much higher can the share price go ?
To answer these questions, there is a need to find out how much profit, Japan will contribute to Biosensors.
Nomura is projecting a normalised (ie without exceptionals) net profit of approx US$51m for end mar 2011, and a net profit of US$77.9m for end mar 2012. How accurate is this ?, especially for 2012, as 2011 profit looks very likely.
First, looking at the experience of Abbot and Boston Scientific, when they introduced the Xience/Promus (both are the same product), they have captured closed to 70 % of the Japanese mkt, in 1 yr, ie approx US$420m (taking Japan mkt size of 600m x 0.70).
What about Terumo's Nobori ?. It looks like the Japanese like new technology, and Nobori is 'new technology', with no polymer after 6-9 mths. Also, It is said that Japanese likes to support their own companies.
SO, Terumo has 2 ADVANTAGES.
If Terumo takes a 20 % mkt share, the revenue is US$120m. Assuming a 1/3 net profit to Biosensors, the net profit accruing to Biosensors is US$36m.
If Terumo takes a 30 % mkt share, the revenue is US$180m, and net profit to Biosensors is US$54m. (If you compare that Biosensors will only earned US$51m for the whole of 2011, this is a significant increase !, if it is true)
SO, looking at potential profit contributions from Japan, we can probably decide how much Biosensors will be worth, by analysing the PE ratio, etc.
Considering that I am neither an analyst or a tipster, it is better to take the whole scenario with a large pinch of salt !
The assumptions of mkt share for Terumo may turn out to be not true, while the 1/3 licensing fee from Terumo is only a guesstimate and bear in mind that we are talking abt a 1 yr time frame for the mkt share to be obtained.
Again, NOT a call to buy/sell.
I went in at $1.16 to test the market with 5 lots. Target is $1.22 and hope it soon arrives there. Cheers.
lowchia ( Date: 11-Mar-2011 22:41) Posted:
|
On Friday, Biosensors re-test the resistance at $1.18 and closed at $1.18 with LOW volume of 6.8 million shares traded.
A white candle stick with no upper/lower shadow affirms that investors have no qualms on buying the stocks higher.
RSI & MACD are bullish though RSI began to trend sideway.
Important Resistance of Biosensors: $1.18
Immediate Support of Biosensors: $1.15
Currently prices are well above the 20/50/100/200 days MA.
On 9/Mar, prices re-test the critical resistance at $1.18 but.............READ MORE
Agreed, but I want to say that sometimes they may " alibaba" us, like they wanted people to buy at the current market price of say $1.20 but they painted their target as $1.80 and trap those green horns of their hard earned money. This is my opinion and I don't know if more lau-chiaos. (Old birds) think of this. New legs (new kakis definitely may not know.). Hahaha..
An analyst is not a tipster, and neither is a tipster an analyst. Which ever, both should be taken with a pinch a salt.
The role of an analyst should be to analyse all the facts about a company, and present it clearly, so that investors can judge for themselves, whether it is a good company or not.
When an analyst has done the above, it is of use to investors, who may not have the time or ability to do it.
ALso, any assumptions made by the analyst should be scrutinised - Is it logical, does it have any basis ? etc.
But an analyst does fulfill a useful role, as they have access to the mgmt of the company, and they can ask hopefully intelligent questions, so that investors can get a better appreciation of the company.
Having said that, each investor should think for themselves, and analyse the facts themselves, to see whether the company is as valuable as the analyst thinks, in terms of PE ratio, P/B, future prospects, growth, competition, etc.
A personal observation. Not a call to buy/sell, And not a call to defend the analysts.
All analysts' recommendations must be taken with a pinch of salt. Nobody in the world will ask you to make money out of their work, sometimes real hard work. Sometimes the opposite is true through subtle talk just like making you a fish to bite their baits which might be empty baits but attractive ones. This is how fisherman go about netting fishes. So newbies should think hard on this. Never listen to tips of tipsters you do not personally know. Otherwise regret will be too late.
I told you so. Cheers.
hotokee ( Date: 07-Mar-2011 09:09) Posted:
|
The joy ride might be over for some - after all Biosensors has gone up from a low of 0.97 to the recent high of 1.20 - no mean feat, and it just goes to show that at times the fundamentals of a stock can and do overide the technical weakness as seen from the charts, when it broke down below the 1.10 , sometime time ago.
However, I would still focus on the impending issues, that are going to come out.
. Imminent approval of the Nobori DES in Japan
. Approval of the Biomatrix in China. ( I dont think Hony and the other 2 partners are going to sit there idling.
. Continued strong organic growth in Europe, Asia and China thru JWMS.
A personal opinion. Not a call to buy/sell.
And it is true that the technicals are looking a little bit tired. ( Is it a breather ? or is it going to go for a deeper correction? - Anybody knows ?)
The joy ride is over for me. Took profit and run liao. Good luck to those still holding. 
bishan22 ( Date: 10-Mar-2011 08:01) Posted:
|
Yup... There's a good chance of a 'pengsan" for this one too... 
bishan22 ( Date: 10-Mar-2011 08:01) Posted:
|
Bearish indicator spotted, may drop today. Good luck.
Hi..would like to know how long does it usually takes for dividend to be credited to bank a/c after ex div date.
Yah, Bro metaphoricsymbol spot on time round.
Amazing, BIG behave according to what he has predicted.
gbleng ( Date: 09-Mar-2011 13:17) Posted:
|
Nomura reccomends BUY with Target Price of $1.50
Action
We lift PT and earnings for BIG on the back of imminent approval for Terumo’s
Nobori stent and strong earnings momentum in 3Q. With a US$1.3bn market cap,
BIG is no longer a start-up. The S$200mn placement has further strengthened the
group’s balance sheet, enabling it to evaluate M& A opportunities. Reaffirming BUY.
Catalysts
Continued momentum in its forthcoming results, the potential value-unlocking of its
50% stake in domestic drug-eluting stent (DES) manufacturer in China, JWMS, and
Japanese approval of Terumo’s Nobori, whose technology is licensed from BIG.
Anchor themes
The US$5bn DES industry is one of the most profitable segments in the medical
technology space, with market share changes driven by innovation. Start-ups like
Biosensors, with its leading-edge technology, could be M& A targets for incumbents
Japan – the next leg of growth
Raising EPS by 11-27% in FY12/13F (Mar-end)
We are raising our forecast by 11% and 27% for FY12/13F to factor in
the strong 3Q earnings momentum and the higher contribution from
Japan in view of the imminent approval for Nobori. We believe
Nobori’s market share in Japan will be boosted by the 3,200-patient
clinical trial, enrolment for which is expected to begin in May.
Strong revenue momentum for 9MFY11
The group saw strong revenue momentum for 9MFY11 (+34% y-y),
driven by further market share gains for BioMatrix/Nobori. We believe
this momentum can be sustained with organic market share gains in
Asia, and the introduction of new products such as the bifurcation
stent and BioFreedom stent. We believe the market is yet to fully
appreciate the significance of BioFreedom — CE Mark approval is
expected in FY12 and this would be a strong endorsement of BIG’s
ability to grow.
JWMS continues to be a key contributor
3QFY11 JWMS contributions remain robust (+43%y-y), despite
market concerns over ASP pressure. We continue to expect strong
performance from the JV, underpinned by volume growth according
to Millennium Research, the Chinese DES market could overtake
Japan this year and is estimated to be worth US$900mn by 2014.
Reiterate BUY – three pillars of growth
BIG is no longer a start-up company. Its growth is underpinned by: i)
core franchise with a significant market share (~15%), ii) 50%-owned
JWMS, the number two player in China, iii) accelerating royalties from
Terumo (upon Nobori’s approval in Japan). With net cash of
US$188mn, the group is well-positioned to drive M& A, further
boosting earnings and competitiveness.
Good Luck
pls hit my target price of 1.25 soon.